• Patients are eligible to be included in the study only if they meet all the following criteria:

• Type of Patient and Disease Characteristics

• Are at least 18 years of age

• Have a clinical diagnosis of Ocular Mucous Membrane Pemphigoid

• a. The treating ophthalmologist will have excluded alternative etiologies that can cause cicatrizing conjunctivitis such as:

⁃ Rosacea

⁃ Atopic dermatitis

⁃ Lichen Planus

⁃ Iatrogenic interventions, e.g. glaucoma eye drops

⁃ Stevens-Johnsons Syndrome

⁃ Graft vs Host Disease

• Have active disease based on ophthalmologic exam

• Patient Characteristics

• Nonpregnant, nonbreastfeeding female or male patient

∙ Female patients of child-bearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with the opposite sex.

‣ Total abstinence is defined as refraining from intercourse during the entirety of the study and for at least 1 week following the last dose of investigational product. Periodic abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception.

‣ Otherwise, female patients of childbearing potential must agree to use 2 effective methods of contraception, where at least 1 form is highly effective, for the entirety of the study and for at least 1 week following the last dose of investigational product.

‣ The following contraception methods are considered acceptable (the patient should choose 2, and 1 must be highly effective \[defined as less than 1% failure rate per year when used consistently and correctly\]):

⁃ Highly effective birth control methods:

∙ Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal

‣ Progestogen- only containing hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal

‣ intrauterine device (IUD)/intrauterine hormone-releasing system (IUS)

‣ vasectomized male (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).

• Effective birth control methods:

⁃ o Male or female condom with spermicide. It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.

• Diaphragm with spermicide

• Cervical sponge

• Cervical cap with spermicide Note: When local guidelines concerning highly effective or effective methods of birth control differ from the above, the local guidelines must be followed.

• Female patients of non-child-bearing potential are not required to use birth control and they are defined as:

⁃ Women who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation)

⁃ Post-menopausal - defined either as

‣ o A woman at least 50 years of age with an intact uterus, not on hormone therapy, who has either

⁃ Cessation of menses for at least 1 year

⁃ At least 6 months of spontaneous menorrhea with follicle-stimulating hormone \>40 mIU/mL

• Women aged 55 years or older who are not on hormone therapy, and who have had at least 6 months of spontaneous amenorrhea

∙ Women aged 55 years or older who have a diagnosis of menopause

• Informed Consent

• Must read and understand the informed consent approved by the institutional review board (IRB)/ethics review board (ERB) governing the site and provide written informed consent.